| Year |
Citation |
Score |
| 2023 |
Antonarakis ES, Subudhi SK, Pieczonka CM, Karsh LI, Quinn DI, Hafron JM, Wilfehrt HM, Harmon M, Sheikh NA, Shore ND, Petrylak DP. Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37058234 DOI: 10.1158/1078-0432.CCR-22-3832 |
0.322 |
|
| 2023 |
Siddiqui BA, Chapin BF, Jindal S, Duan F, Basu S, Yadav SS, Gu AD, Espejo AB, Kinder M, Pettaway CA, Ward JF, Tidwell RSS, Troncoso P, Corn PG, Logothetis CJ, ... ... Subudhi SK, et al. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). Journal For Immunotherapy of Cancer. 11. PMID 36948506 DOI: 10.1136/jitc-2022-006262 |
0.322 |
|
| 2022 |
Goswami S, Siddiqui BA, Subudhi SK, Basu S, Yadav SS, Diab A, Sharma P. A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events. Cancer Cell. 40: 249-251. PMID 35290784 DOI: 10.1016/j.ccell.2022.02.015 |
0.336 |
|
| 2021 |
Subudhi SK, Siddiqui BA, Aparicio AM, Yadav SS, Basu S, Chen H, Jindal S, Tidwell RSS, Varma A, Logothetis CJ, Allison JP, Corn PG, Sharma P. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. Journal For Immunotherapy of Cancer. 9. PMID 34663638 DOI: 10.1136/jitc-2021-002919 |
0.314 |
|
| 2021 |
Sinha M, Zhang L, Subudhi S, Chen B, Marquez J, Liu EV, Allaire K, Cheung A, Ng S, Nguyen C, Friedlander TW, Aggarwal R, Spitzer M, Allison JP, Small EJ, et al. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. Journal For Immunotherapy of Cancer. 9. PMID 33986125 DOI: 10.1136/jitc-2020-002254 |
0.377 |
|
| 2020 |
Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, Simsek B, Saci A, Hu Y, Han GC, Fizazi K. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell. PMID 32916128 DOI: 10.1016/J.Ccell.2020.08.007 |
0.37 |
|
| 2020 |
Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, et al. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. PMID 32675015 DOI: 10.1016/J.Clgc.2020.05.013 |
0.323 |
|
| 2020 |
Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, Thall P, Wu CJ, et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Science Translational Medicine. 12. PMID 32238575 DOI: 10.1126/Scitranslmed.Aaz3577 |
0.529 |
|
| 2020 |
Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, et al. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31941830 DOI: 10.1158/1078-0432.Ccr-19-2389 |
0.318 |
|
| 2020 |
Viscuse PV, Zhang M, Liu J, Slack Tidwell R, Subudhi SK, Zurita AJ, Corn PG, Tu S, Araujo JC, Wang J, Efstathiou E, Wang J, Pilie PG, Troncoso P, Zhang J, et al. Linking the Aggressive Variant Prostate Cancer (AVPC) molecular signature (-ms) to androgen indifference in a prospective clinical trial. Journal of Clinical Oncology. 38: 156-156. DOI: 10.1200/Jco.2020.38.6_Suppl.156 |
0.328 |
|
| 2020 |
Efstathiou E, Boukovala MA, Spetsieris N, Wen S, Hoang A, Weldon JA, Tidwell R, Davis JW, Chapin BF, Corn PG, Subudhi SK, Aparicio A, Pettaway CA, Pisters LL, Papadopoulos JN, et al. Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC). Journal of Clinical Oncology. 38: 5504-5504. DOI: 10.1200/Jco.2020.38.15_Suppl.5504 |
0.341 |
|
| 2019 |
Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan B, Miura Y, Sharma P. Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Cell. 179: 1177-1190.e13. PMID 31730856 DOI: 10.1016/J.Cell.2019.10.029 |
0.485 |
|
| 2019 |
Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, Subudhi SK, Tawbi H, Keung E, Wargo J, Allison JP, Sharma P. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America. PMID 31611368 DOI: 10.1073/Pnas.1908079116 |
0.321 |
|
| 2019 |
Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. The Lancet. Oncology. PMID 31515154 DOI: 10.1016/S1470-2045(19)30408-5 |
0.318 |
|
| 2019 |
Vence L, Bucktrout SL, Fernandez Curbelo I, Blando J, Smith BM, Mahne AE, Lin JC, Park T, Pascua E, Chaparro-Riggers J, Subudhi SK, Borin Scutti J, Higa MG, Zhao H, Yadav SS, et al. Characterization and comparison of GITR expression in solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31358539 DOI: 10.1158/1078-0432.Ccr-19-0289 |
0.333 |
|
| 2019 |
Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, Chiari R, De Giglio A, Sleiman J, Funchain P, Wills B, Zhang J, Naidoo J, ... ... Subudhi SK, et al. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900320. PMID 31163011 DOI: 10.1200/Jco.19.00320 |
0.313 |
|
| 2019 |
Sharma A, Subudhi SK, Blando J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 3469-3470. PMID 31160495 DOI: 10.1158/1078-0432.CCR-19-0402 |
0.397 |
|
| 2019 |
Sharma P, Pachynski RK, Narayan V, Flechon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, Duan T, Saci A, Hu S, Han GC, Fizazi K. Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650). Journal of Clinical Oncology. 37: 142-142. DOI: 10.1200/Jco.2019.37.7_Suppl.142 |
0.334 |
|
| 2019 |
Subudhi SK, Aparicio A, Zurita AJ, Doger B, Kelly WK, Peer A, Rathkopf DE, Karsh LI, Tryon JJ, Kothari N, Zhao X, Zhu E, Ricci DS, Tran N, De Bono JS. A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350). Journal of Clinical Oncology. 37: TPS5087-TPS5087. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps5087 |
0.35 |
|
| 2019 |
Drake CG, Pachynski RK, Subudhi SK, McNeel DG, Antonarakis ES, Bauer TM, Patricia D, Wade M, Zudaire E, Mason G, Knoblauch RE, Stone NL, Infante JR, Gottardis M, Fong L. Safety and preliminary immunogenicity of JNJ-64041809, a live attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 37: e16509-e16509. DOI: 10.1200/Jco.2019.37.15_Suppl.E16509 |
0.373 |
|
| 2019 |
Siddiqui BA, Durand J, Gao J, Wang J, Aparicio A, Campbell MT, Siefker-Radtke AO, Tannir NM, Corn PG, Msaouel P, Shah AY, Zurita AJ, Tu S, Suarez-Almazor ME, Sudhakar T, ... ... Subudhi SK, et al. Clinical and immunological analyses of immune checkpoint inhibitor-associated neuromuscular (NM) toxicities. Journal of Clinical Oncology. 37: e14118-e14118. DOI: 10.1200/Jco.2019.37.15_Suppl.E14118 |
0.325 |
|
| 2019 |
Chapin BF, Wang X, Zhang M, Corn PG, Zurita AJ, Elsheshtawi MA, Davis JW, Pettaway CA, Adibi M, Gleave M, Cooperberg MR, Smaldone MC, Mcguire SE, Tu S, Wang J, ... Subudhi SK, et al. Complex biologic heterogeneity of de novo hormone naïve metastatic prostate cancer (HNPCa): Comparison of early progressors and prolonged responders to initial systemic treatment. Journal of Clinical Oncology. 37: 5055-5055. DOI: 10.1200/Jco.2019.37.15_Suppl.5055 |
0.319 |
|
| 2019 |
Aparicio A, Zhang M, Ramesh N, Wang X, Corn PG, Zurita AJ, Davis JW, Pettaway CA, Adibi M, Mcguire SE, Tu S, Wang J, Subudhi SK, Elsheshtawi MA, Efstathiou E, et al. Aggressive variant prostate cancer (AVPC) molecular signature in castration-sensitive, de novo metastatic prostate cancer (M1PCa). Journal of Clinical Oncology. 37: 5052-5052. DOI: 10.1200/Jco.2019.37.15_Suppl.5052 |
0.338 |
|
| 2019 |
Tran B, Kouros-Mehr H, Fermin A, Horvath L, Roncolato F, Rettig M, Dorff T, Tagawa S, Subudhi S, Antonarakis E, Armstrong A, Petrylak D, Fizazi K, Salvati M, Scher H. A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) Annals of Oncology. 30: v353. DOI: 10.1093/Annonc/Mdz248.052 |
0.412 |
|
| 2018 |
Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, ... ... Subudhi SK, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nature Medicine. PMID 30420754 DOI: 10.1038/S41591-018-0238-9 |
0.353 |
|
| 2018 |
Choi K, Abu-Sbeih H, Samdani R, Nogueras Gonzalez G, Raju GS, Richards DM, Gao J, Subudhi S, Stroehlein J, Wang Y. Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity? Inflammatory Bowel Diseases. PMID 30169584 DOI: 10.1093/Ibd/Izy240 |
0.301 |
|
| 2018 |
Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo JA, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30054281 DOI: 10.1158/1078-0432.Ccr-18-0762 |
0.508 |
|
| 2018 |
Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, Xiong L, Trojer P, Aparicio A, Subudhi SK, Allison JP, Zhao H, Sharma P. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. The Journal of Clinical Investigation. PMID 29905573 DOI: 10.1172/Jci99760 |
0.551 |
|
| 2017 |
Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemotherapy and Pharmacology. PMID 28730293 DOI: 10.1007/S00280-017-3391-9 |
0.407 |
|
| 2017 |
Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine. PMID 28346412 DOI: 10.1038/Nm.4308 |
0.365 |
|
| 2017 |
Corn PG, Zurita AJ, Subudhi SK, Tu S, Aparicio A, Araujo JC, Kim J, Wang J, Efstathiou E, Pagliaro LC, Logothetis C. Cabozantinib plus androgen deprivation therapy in patients with androgen-dependent metastatic prostate cancer. Journal of Clinical Oncology. 35: 169-169. DOI: 10.1200/Jco.2017.35.6_Suppl.169 |
0.338 |
|
| 2017 |
Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis C, Wistuba II, Wargo JA, et al. Investigation of mechanisms of resistance to ipilimumab therapy with a pre-surgical trial in patients with high-risk, localized prostate cancer. Journal of Clinical Oncology. 35: 5081-5081. DOI: 10.1200/Jco.2017.35.15_Suppl.5081 |
0.42 |
|
| 2017 |
Subudhi SK, Aparicio A, Troncoso P, Zhang J, Gumbs C, Wu C, Gao J, Vence LM, Blando JM, Corn PG, Araujo JC, Zurita AJ, Prokhorova IN, Van Alstine M, Logothetis C, et al. Linking tumor mutational load to clinical responses to ipilimumab (IPI) in men with advanced prostate cancer (PCa). Journal of Clinical Oncology. 35: 5065-5065. DOI: 10.1200/Jco.2017.35.15_Suppl.5065 |
0.347 |
|
| 2016 |
Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America. PMID 27698113 DOI: 10.1073/Pnas.1611421113 |
0.519 |
|
| 2016 |
Miyahira AK, Roychowdhury S, Goswami S, Ippolito JE, Priceman SJ, Pritchard CC, Sfanos KS, Subudhi SK, Simons JW, Pienta KJ, Soule HR. Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. The Prostate. PMID 27679977 DOI: 10.1002/Pros.23260 |
0.307 |
|
| 2016 |
Shi LZ, Fu T, Guan B, Chen J, Blando JM, Allison JP, Xiong L, Subudhi SK, Gao J, Sharma P. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nature Communications. 7: 12335. PMID 27498556 DOI: 10.1038/Ncomms12335 |
0.367 |
|
| 2016 |
Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. Journal For Immunotherapy of Cancer. 4: 36. PMID 27330809 DOI: 10.1186/S40425-016-0139-8 |
0.406 |
|
| 2016 |
Goswami S, Aparicio A, Subudhi SK. Immune Checkpoint Therapies in Prostate Cancer. Cancer Journal (Sudbury, Mass.). 22: 117-20. PMID 27111907 DOI: 10.1097/Ppo.0000000000000176 |
0.364 |
|
| 2016 |
Subudhi SK, Aparicio A, Troncoso P, Zhang J, Gumbs C, Wu C, Vence LM, Logothetis C, Futreal A, Allison JP, Sharma P. A feasibility study to determine T cell responses to neoantigens following treatment with ipilimumab in men with metastatic castration-resistant prostate carcinoma (mCRPC). Journal of Clinical Oncology. 34: e14506-e14506. DOI: 10.1200/Jco.2016.34.15_Suppl.E14506 |
0.44 |
|
| 2016 |
Subudhi SK, Aparicio A, Gao J, Zurita-Saavedra A, Araujo JC, Logothetis CJ, Brinda KR, Allison JP, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Sharma P. Abstract 1402: Exploratory biomarkers that predict for clinical outcomes in a Phase II trial with ipilimumab plus finite androgen deprivation therapy for metastatic non-castrate prostate cancer Cancer Research. 76: 1402-1402. DOI: 10.1158/1538-7445.Am2016-1402 |
0.409 |
|
| 2015 |
Gao J, He Q, Subudhi S, Aparicio A, Zurita-Saavedra A, Lee DH, Jimenez C, Suarez-Almazor M, Sharma P. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene. PMID 25659583 DOI: 10.1038/Onc.2015.5 |
0.331 |
|
| 2015 |
Chapin BF, Mcguire SE, Wang X, Troncoso P, Davis JW, Navai N, Subudhi SK, Zurita AJ, Araujo JC, Pettaway CA, Matin SF, Pisters LL, Ward JF, Tu S, Wang J, et al. A prospective, multicenter, randomized phase II trial of best systemic therapy (BST) or BST plus definitive treatment (Surgery or Radiation) of the primary tumor in metastatic prostate cancer. Journal of Clinical Oncology. 33: TPS5075-TPS5075. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps5075 |
0.327 |
|
| 2015 |
Corn PG, Tu S, Zurita AJ, Subudhi SK, Araujo JC, Kim J, Jonasch E, Pagliaro LC, Siefker-Radtke AO, Wang J, Wang X, Heath EI, Logothetis C, Aparicio A. A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 33: 5010-5010. DOI: 10.1200/Jco.2015.33.15_Suppl.5010 |
0.335 |
|
| 2015 |
Subudhi SK, Aparicio A, Gao J, Zurita A, John A, Logothetis C, Rao B, Vence L, Allison J, Emerson RO, Yusko E, Vignali M, Robins H, Sun JJ, Sharma P. Immune correlates in a Phase II clinical trial with ipilimumab in combination with finite androgen deprivation therapy in patients with metastatic non-castrate prostate cancer Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P106 |
0.333 |
|
| 2014 |
Subudhi SK, Aparicio A, Zurita AJ, Araujo JC, Corn PG, Tu S, Wang X, Harris DR, Winslow KA, Gao J, Logothetis CJ, Sharma P. 1053PDFINITE ANDROGEN DEPRIVATION THERAPY (ADT) PLUS IPILIMUMAB (IPI) IN MEN WITH HORMONE-NAïVE METASTATIC PROSTATE CANCER (HN-MPCA). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv363. PMID 28171240 DOI: 10.1093/Annonc/Mdu342.6 |
0.466 |
|
| 2014 |
Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Science Translational Medicine. 6: 226ra32. PMID 24598590 DOI: 10.1126/Scitranslmed.3008095 |
0.405 |
|
| 2014 |
Zamarin D, Holmgaard RB, Subudhi SK, Park J, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus. Journal of Clinical Oncology. 32: 3051-3051. DOI: 10.1200/Jco.2014.32.15_Suppl.3051 |
0.374 |
|
| 2013 |
Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 155: 1309-22. PMID 24315100 DOI: 10.1016/J.Cell.2013.11.012 |
0.346 |
|
| 2013 |
Reis BS, Jungbluth AA, Frosina D, Holz M, Ritter E, Nakayama E, Ishida T, Obata Y, Carver B, Scher H, Scardino PT, Slovin S, Subudhi SK, Reuter VE, Savage C, et al. Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6112-25. PMID 24081977 DOI: 10.1158/1078-0432.Ccr-12-3580 |
0.342 |
|
| 2013 |
Zamarin D, Holmgaard R, Subudhi S, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-O9 |
0.411 |
|
| 2012 |
Oh WK, Kantoff P, Scher HI, Magidson J, Wassmann K, Lee GM, Katz LM, Subudhi SK, Anand A, Fleisher M, Galsky MD, Ross RW. A validated whole-blood RNA transcript-based prognostic model that predicts survival in men with castration-resistant prostate cancer. Journal of Clinical Oncology. 30: 4516-4516. DOI: 10.1200/Jco.2012.30.15_Suppl.4516 |
0.325 |
|
| 2011 |
Subudhi SK, Heller G, Anand A, Danila DC, Fleisher M, Scher HI. A six-gene panel that predicts survival in men with castration-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4539. PMID 28023419 DOI: 10.1200/Jco.2011.29.15_Suppl.4539 |
0.339 |
|
| 2005 |
Anders RA, Subudhi SK, Wang J, Pfeffer K, Fu YX. Contribution of the lymphotoxin beta receptor to liver regeneration. Journal of Immunology (Baltimore, Md. : 1950). 175: 1295-300. PMID 16002734 DOI: 10.4049/Jimmunol.175.2.1295 |
0.537 |
|
| 2005 |
Wang Y, Subudhi SK, Anders RA, Lo J, Sun Y, Blink S, Wang Y, Wang J, Liu X, Mink K, Degrandi D, Pfeffer K, Fu YX. The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. The Journal of Clinical Investigation. 115: 711-7. PMID 15696194 DOI: 10.1172/JCI22982 |
0.729 |
|
| 2005 |
Subudhi SK, Alegre ML, Fu YX. The balance of immune responses: costimulation verse coinhibition. Journal of Molecular Medicine (Berlin, Germany). 83: 193-202. PMID 15630593 DOI: 10.1007/S00109-004-0617-1 |
0.58 |
|
| 2005 |
Wang Y, Subudhi SK, Anders RA, Lo J, Sun Y, Blink S, Wang Y, Wang J, Liu X, Mink K, Degrandi D, Pfeffer K, Fu YX. The role of herpesvirus entry mediator as a negative regulator of T cell–mediated responses Journal of Clinical Investigation. 115: 711-717. DOI: 10.1172/Jci200522982 |
0.74 |
|
| 2004 |
Baron BW, Anastasi J, Montag A, Huo D, Baron RM, Karrison T, Thirman MJ, Subudhi SK, Chin RK, Felsher DW, Fu YX, McKeithan TW, Baron JM. The human BCL6 transgene promotes the development of lymphomas in the mouse. Proceedings of the National Academy of Sciences of the United States of America. 101: 14198-203. PMID 15375218 DOI: 10.1073/Pnas.0406138101 |
0.689 |
|
| 2004 |
Subudhi SK, Zhou P, Yerian LM, Chin RK, Lo JC, Anders RA, Sun Y, Chen L, Wang Y, Alegre ML, Fu YX. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. The Journal of Clinical Investigation. 113: 694-700. PMID 14991067 DOI: 10.1172/Jci19210 |
0.733 |
|
| 2003 |
Sun Y, Subudhi SK, Fu YX. Co-stimulation agonists as a new immunotherapy for autoimmune diseases. Trends in Molecular Medicine. 9: 483-9. PMID 14604826 DOI: 10.1016/J.Molmed.2003.09.011 |
0.608 |
|
| 2003 |
Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, Strom TB, Bluestone JA. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. Journal of Immunology (Baltimore, Md. : 1950). 171: 3348-52. PMID 14500627 DOI: 10.4049/Jimmunol.171.7.3348 |
0.338 |
|
| 2002 |
Sun Y, Chen HM, Subudhi SK, Chen J, Koka R, Chen L, Fu YX. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nature Medicine. 8: 1405-13. PMID 12426559 DOI: 10.1038/Nm1202-796 |
0.598 |
|
| 2002 |
Tang Q, Subudhi SK, Henriksen KJ, Long CG, Vives F, Bluestone JA. The Src family kinase Fyn mediates signals induced by TCR antagonists. Journal of Immunology (Baltimore, Md. : 1950). 168: 4480-7. PMID 11970992 DOI: 10.4049/Jimmunol.168.9.4480 |
0.417 |
|
| 2002 |
Sun Y, Lin X, Chen HM, Wu Q, Subudhi SK, Chen L, Fu YX. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. Journal of Immunology (Baltimore, Md. : 1950). 168: 1457-65. PMID 11801689 DOI: 10.4049/Jimmunol.168.3.1457 |
0.663 |
|
| 2001 |
Tesciuba AG, Subudhi S, Rother RP, Faas SJ, Frantz AM, Elliot D, Weinstock J, Matis LA, Bluestone JA, Sperling AI. Inducible costimulator regulates Th2-mediated inflammation, but not Th2 differentiation, in a model of allergic airway disease. Journal of Immunology (Baltimore, Md. : 1950). 167: 1996-2003. PMID 11489981 DOI: 10.4049/Jimmunol.167.4.1996 |
0.387 |
|
| Show low-probability matches. |